OA20.04 Survival of Patients with Persistent N1 or N2 Disease After Induction Therapy for Stage IIIA-N2 Non-Small-Cell Lung Cancer

2021 ◽  
Vol 16 (10) ◽  
pp. S884
Author(s):  
J. Beqari ◽  
A. Potter ◽  
M. Pan ◽  
J. Copeland ◽  
M. Lanuti ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Induction Therapy ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Stage Iiia ◽  
N2 Disease

scholarly journals Clinical Predictors of Persistent Mediastinal Nodal Disease After Induction Therapy for Stage IIIA N2 Non-Small Cell Lung Cancer

2017 ◽  
Vol 103 (1) ◽  
pp. 281-286 ◽  
Author(s):  
Mohamed K. Kamel ◽  
Mohamed Rahouma ◽  
Galal Ghaly ◽  
Abu Nasar ◽  
Jeffrey L. Port ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Induction Therapy ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Nodal Disease ◽  
Small Cell Lung ◽  
Clinical Predictors ◽  
Stage Iiia

Gemcitabine and Cisplatin as Induction Regimen for Patients With Biopsy-Proven Stage IIIA N2 Non–Small-Cell Lung Cancer: A Phase II Study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955)

2000 ◽  
Vol 18 (14) ◽  
pp. 2658-2664 ◽  
Author(s):  
N. Van Zandwijk ◽  
E.F. Smit ◽  
G.W. P. Kramer ◽  
F. Schramel ◽  
S. Gans ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Induction Chemotherapy ◽  
Induction Therapy ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
World Health ◽  
Small Cell Lung ◽  
Stage Iiia ◽  
Induction Regimen

PURPOSE: Our objective was to better define the activity/feasibility of gemcitabine/cisplatin (GC) as induction chemotherapy in patients with stage IIIA N2 non–small-cell lung cancer (NSCLC) followed by surgery or radiotherapy within a large, ongoing comparative study (EORTC 08941). PATIENTS AND METHODS: Forty-seven chemotherapy-naive patients with NSCLC, median age of 58 years, stage IIIA N2 disease, World Health Organization performance status of 0 or 1, and the ability to tolerate a pneumonectomy received gemcitabine 1,000 mg/m2 on days 1, 8, and 15 and cisplatin 100 mg/m2 on day 2, every 4 weeks. Patients received induction chemotherapy (three cycles) before re-evaluation and randomization to surgery or radiotherapy. RESULTS: Grade 3/4 thrombocytopenia, the main hematologic toxicity, occurred in 60% of patients but was not associated with bleeding. Full-dose gemcitabine was given in 48% of the courses. Severe nonhematologic toxicity was uncommon. Two patients with preexisting, autoimmune pulmonary fibrosis had deterioration of pulmonary function after radiotherapy. Thirty-three (70.2%; 95% confidence interval, 55.1% to 82.7%) of the 47 eligible patients had objective responses (three complete responses and 30 partial responses). Mediastinal nodes were tumor-free after induction therapy in 53% of cases. Resections were considered complete in 71% of the patients who underwent thoracotomy after induction therapy. Median survival for all recruited patients (N = 53) was 18.9 months, with an estimated 1-year survival rate of 69%. CONCLUSION: In patients with N2 stage IIIA NSCLC, GC is a highly active and well-tolerated induction regimen. GC should be explored in combination with surgery or radiotherapy in stage I and II patients.

scholarly journals Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer

2017 ◽  
Vol 103 (4) ◽  
pp. 1070-1075 ◽  
Author(s):  
Pamela Samson ◽  
Traves D. Crabtree ◽  
Cliff G. Robinson ◽  
Daniel Morgensztern ◽  
Stephen Broderick ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Induction Therapy ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Time Interval ◽  
Small Cell Lung ◽  
Stage Iiia ◽  
The Ideal

The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer

Lung Cancer ◽  
2003 ◽  
Vol 42 (1) ◽  
pp. 69-77 ◽  
Author(s):  
Noriyoshi Sawabata ◽  
Steven M. Keller ◽  
Akihide Matsumura ◽  
Osamu Kawashima ◽  
Tatsuhiko Hirono ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Induction Therapy ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
N2 Disease ◽  
Multi Level ◽  
The Impact

scholarly journals Incorporating Surgery in treatment of Stage IIIA – N2 Non- Small Cell Lung Cancer

2021 ◽  
Vol 5 (1) ◽  
pp. 33-43
Author(s):  
Binay Thakur ◽  
Mukti Devkota
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Multimodality Treatment ◽  
Small Cell ◽  
Small Cell Lung ◽  
Stage Iiia ◽  
Select Group ◽  
N2 Disease ◽  
Single Station

Stage IIIA-N2 Non-small cell lung cancer includes heterogenous group of patients with a poor 5-year survival ranging from 13% to 36% with surgery alone. Various randomized controlled trials established the role of multimodality treatment either including or excluding surgical resection. In a select group of non-bulky/ single station N2 disease, the better results have been achieved with induction chemotherapy or chemo-radiotherapy followed by surgery. 

Sign in / Sign up

Export Citation Format

Share Document